The contraband arrived the way it so often does: tucked into truck cabs, passed across border counters, laid out on the tables of street vendors who promised relief in a bottle.
By the time the Botswana Medicines Regulatory Authority had finished counting, the haul told its own quiet story of a trade that thrives in the gaps – 2.8 tonnes of illegal and unauthorised medicinal products, worth more than P500,000, gathered up and condemned to destruction.
The seizures, announced on 5th November, capped a coordinated enforcement and market-surveillance campaign that ran from Oct. 23 to Oct. 30 and reached into some of the country’s busiest crossings and corridors: Martin’s Drift Border Gate, Palapye, the Mamuno Border Gate, Kasane, Kazungula and Pandamatenga. The authority, known as BoMRA, did not act alone. It moved in concert with Port Health, Environmental Health, the Botswana Unified Revenue Service and the Botswana Police Service – a multi-agency column that turned its attention to trading facilities, street vendors and vehicles alike, among them trucks, public transport and private cars, hunting for medicines on the move and for sale outside the law.
What the operations surfaced was not a single rogue product but a varied inventory of risk. More than 20,000 units were ultimately destroyed, a catalogue that ranged from prescription-only medicines to skin-lightening creams, tablets, soaps, oils and codeine-containing cough syrups – the last a perennial favourite of the informal market and a well-known object of misuse. Products judged illegal or unauthorised were confiscated and consolidated for disposal, pooled together with items that partner agencies had intercepted earlier. BoMRA oversaw every step of the handling and destruction, a chain of custody designed with one purpose in mind: to ensure that nothing could slip back into the medicines supply chain.
The campaign, the authority said, is part of a continuing effort to tighten regulatory oversight, to disrupt the illegal trade in medicinal products, and to shield the public from goods that do not meet Botswana’s regulatory requirements.
A rule that trips up even the well-meaning
At the heart of the authority’s message lies a distinction that is easy to miss and costly to ignore. Medicinal products meant for human or veterinary use, BoMRA reminded the public, must satisfy Botswana’s regulatory requirements – including product registration and import authorisation – before they may be legally imported, distributed or supplied.
And here is the subtlety: registration alone does not open the gate. A product may be registered and still require separate authorisation to be imported. Registration of a medicinal product, the authority stressed, does not automatically authorise its importation.
The reason the rule bites so hard is a matter of what cannot be seen. Unauthorised products may carry significant risks precisely because their quality, safety and efficacy may never have been properly established. Medicines bought through unverified channels can be of uncertain origin, or may have been stored and handled under conditions that quietly degrade them long before they reach a consumer’s hands.
What the authority is asking of the public
BoMRA translated its enforcement push into a set of plain instructions for ordinary buyers. It urged members of the public to:
- Buy responsibly:Purchase medicinal products only from licensed and authorised facilities.
- Be vigilant:Avoid buying medicines from street vendors, informal market sales and unverified online sellers.
- Use medicines safely:Never use prescription-only medicines, including codeine-containing cough syrups, without a valid prescription from an authorised healthcare professional.
- Seek professional advice:Consult a healthcare professional or veterinarian before using any product or treatment intended for humans or animals.
- Report suspicious products:Notify BoMRA or the nearest police station of any suspected illegal medicinal products.
Partnerships as the backbone
If the week’s figures carried a warning, they also carried a note of acknowledgment. BoMRA credited the sustained collaboration of its partner agencies, calling such alliances essential to strengthening surveillance and market control both within communities and across the length of the medicines supply chain. Enforcement, in the authority’s telling, is not a single raid but a standing posture – and it signalled that surveillance and enforcement activities will continue, to detect illegal medicinal products, confront non-compliance and safeguard public health.
Established under the Medicines and Related Substances Act, BoMRA exists to ensure that all human and veterinary medicines, medical devices, cosmetics and related substances meet set standards of quality, safety and efficacy. Its broader ambition, the authority has said, is to deliver transparent market-authorisation services, to reduce the incidence of substandard and falsified medicines, and to build public and industry trust in the systems meant to keep the nation’s medicine cabinet honest.
For now, 2.8 tonnes of that trust-eroding trade has been taken off the roads and out of the markets – reduced, finally, to ash.
